Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2008: Boosted Atazanavir and Lopinavir/ritonavir Have Similar Efficacy, Side Effects Differ across Racial/ethnic Groups

Race-based differences in efficacy and safety have been reported among HIV positive individuals on HAART. However, data on this issue are limited. It is widely known that rates of obesity, diabetes, and the metabolic syndrome are increasing. In addition, studies suggest that certain racial/ethnic groups may be more susceptible to the risks associated with these conditions.

Read more:

A Comparison of the Single-dose Bioavailability of a Ritonavir Tablet Formulation Compared with the Current Soft Gel Capsule

Ritonavir (Norvir) has been approved by regulatory agencies worldwide and is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection. Due to its cytochrome P450 inhibition properties, ritonavir dosed 100 mg once-daily (QD) to 200 mg twice-daily (BID) is frequently used as a pharmacokinetic enhancer of other antiretrovirals, including protease inhibitors.

Read more:

Antiretroviral Therapy is Effective for Injection Drug Users

Injection drug users (IDUs) with HIV can benefit as much from antiretroviral therapy as non-users, according to a study presented Sunday, August 3, in advance of the XVII International AIDS Conference in Mexico City, and published in the August 6 Journal of the American Medical Association.

Read more:

AIDS 2008: Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Patients

Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) has previously demonstrated good efficacy and tolerability in an international Phase 2b trial of treatment-naive patients through 48 weeks. Investigators presented 96-week follow-up data at the XVII International Conference on AIDS taking place this week in Mexico City.alt

Read more:

NRTI Backbone Choice Affects Durability of Efavirenz- or Nevirapine-based HAART in Treatment-naive HIV patients

The calendar year in which HIV patients initiated HAART and durability of the nucleoside/nucleotide reverse transcriptase (NRTI) backbone are significant predictors of virological success and treatment failure, according to a study published in the April 6, 2009 early online edition of the Journal of Acquired Immune Deficiency Syndromes.

Read more:

AIDS 2008: Attitudes and Perceptions about HIV/AIDS among HIV Patients

Results from an international survey of HIV-positive patients – the largest of its kind conducted to date – were released today at the 17th International AIDS Conference (AIDS 2008). Conducted by the International Association of Physicians in AIDS Care (IAPAC), the survey looked at the attitudes and perceptions of nearly 3000 people living with HIV from 18 countries and shows an urgent global need for improved HIV and AIDS understanding and increased dialog about quality of life.

Read more:

100 mg Once- and Twice-daily Ritonavir (Norvir) Decreases HDL and CD36 Expression, but Only Twice-daily Dosing Increases Triglycerides

Most current HIV protease inhibitors (PIs) are used in combination with a low dose of ritonavir (Norvir) to raise their levels in the blood. This has led to interest in determining the impact of low-dose ritonavir on changes in blood lipids among patients using boosted PIsIn the current study, presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008) last month in Boston, researchers investigated the possible role of ritonavir in contributing to cardiovascular disease.

Read more: